Tyrosine-kinase inhibitor
Tyrosine-kinase inhibitors (TKIs) are a class of targeted therapies designed to block the activity of tyrosine kinases, enzymes that transmit growth, survival, and differentiation signals through phosphorylation-dependent signaling pathways.
Tyrosine-kinase inhibitors (TKIs) are a class of targeted therapies designed to block the activity of tyrosine kinases, enzymes that transmit growth, survival, and differentiation signals through phosphorylation-dependent signaling pathways. In oncology, TKIs are used to suppress aberrant kinase-driven tumor proliferation and are especially important in cancers driven by oncogenic kinase signaling, such as EGFR-mutant non-small-cell lung cancer, chronic myeloid leukemia, gastrointestinal stromal tumors, renal cell carcinoma, and hepatocellular carcinoma.
Clinically, TKIs are often used as monotherapy or in combination with other systemic treatments, including immunotherapy, checkpoint inhibitor, and antiangiogenic agents such as apatinib or sorafenib. Their use is shaped by substantial interpatient pharmacokinetic variability, narrow therapeutic windows for some agents, and the frequent emergence of acquired resistance. As a result, TKIs are also a major focus of therapeutic drug monitoring, resistance-genotyping, and biomarker-driven treatment selection.
Where the papers sit
17 papers from the last 6 months study tyrosine-kinase inhibitor directly · updated from PubMed 13 Nov 2026
Study type 3 clinical trials · 5 observational · 6 human data · 3 preclinical
Themes 3 themes · 2 new directions
-
Long-Term CML TKI Management
Chronic myeloid leukemia care is moving beyond response toward durable treatment-free remission and safer long-term TKI use. Molecular relapse surveillance and adherence remain central after imatinib, nilotinib, or dasatinib. Patient-reported monitoring and studies of arterial stiffness address quality of life and vascular risk. Third-generation agents such as vamotinib and TKI maintenance after brexucabtagene autoleucel extend the question to resistant Philadelphia chromosome-positive disease.
6 papers · 35.3%
-
Immunotherapy–TKI Cancer Combinations
Hepatocellular carcinoma work is converging on combinations of TKIs with PD-1 blockade, TACE, radiotherapy, or metabolic therapy. Camrelizumab–apatinib regimens and lenvatinib plus ADI-PEG 20 are being judged by response, progression-free survival, and safety, but much evidence remains early or retrospective. FAP-α-responsive nanoparticles aim to remodel fibrotic stroma and improve drug penetration. The same combination logic appears in PIK3CA-mutant cervical cancer and VEGF-treated renal or thyroid cancer, leaving comparative benefit and toxicity unresolved.
6 papers · 35.3%
-
Resistance in Solid Tumors
EGFR-TKI resistance is being addressed through molecular detection and pharmacologic optimization. NF-κB/ALDH1A1 provides a non-mutational mechanism in non-small cell lung cancer, while biosensors seek resistance mutations. Brain-penetrant inhibitors are being linked to intracranial exposure and response, and HER2 strategies are moving beyond amplification. Mefatinib versus gefitinib adds comparative first-line evidence in EGFR-mutated disease.
5 papers · 29.4%
TKI therapy becomes a finite intervention that can be followed by treatment-free remission
The EURO-SKI biomarker study in chronic myeloid leukemia examined patients after tyrosine-kinase-inhibitor discontinuation and distinguished sustained treatment-free remission from molecular relapse using transcriptomic and immune-cell communication patterns. Rather than treating TKI therapy as necessarily ongoing, it presents treatment cessation—and the biological monitoring of remission afterward—as a therapeutic-management role for the inhibitor 42315627Jun.
Sorafenib can function as a stromal-targeted nanotherapeutic payload in fibrotic hepatocellular carcinoma
The FAP-α-responsive size-transformable lipid nanoparticle study in fibrotic hepatocellular carcinoma incorporated sorafenib with doxorubicin into a carrier that targets activated hepatic stellate cells, responds to tumor fibroblast-associated protease activity, remodels the stromal compartment, and improves drug penetration. This recasts the TKI as one component of an adaptive, stroma-directed delivery system rather than solely as a conventionally administered kinase-blocking drug 42328782Jun.
Papers
The 17 papers from the last 6 months that study tyrosine-kinase inhibitor directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Long-Term CML TKI Management (6)
- Development, validation, and pilot-testing of a comprehensive patient-reported EORTC custom questionnaire for monitoring real-world tyrosine kinase toxicity in chronic myeloid leukemia. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 12 Nov 2026 PMID 43018785
- Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor? Journal of hematology & oncology · 27 Oct 2026 PMID 42934771
- Modifiable determinants of adherence to tyrosine kinase inhibitors in classical myeloproliferative neoplasms: A mixed-methods systematic review protocol. PloS one · 18 Sept 2026 PMID 42758748
- Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study. Leukemia research · 4 Aug 2026 PMID 42551129
- Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. Blood advances · 25 Jun 2026 PMID 42349018
- Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study. Leukemia · 18 Jun 2026 PMID 42315627
Immunotherapy–TKI Cancer Combinations (6)
- Retrospective observational study of transcatheter arterial chemoembolization (TACE) combined with PD-1 inhibitor and tyrosine kinase inhibitor (TKI) in advanced hepatocellular carcinoma. Medicine · 17 Oct 2026 PMID 42888556
- Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation. PloS one · 29 Sept 2026 PMID 42809552
- The Combined Therapeutic Effect of Lenvatinib and ADI-PEG 20 in Advanced Hepatocellular Carcinoma: A Case Report. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379775
- Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377073
- FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma. ACS applied materials & interfaces · 22 Jun 2026 PMID 42328782
- Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. Hypertension (Dallas, Tex. : 1979) · 20 May 2026 PMID 42158981
Resistance in Solid Tumors (5)
- A Systematic Intracranial Exposure-Response Evaluation of Brain-Penetrant Inhibitors: Informing Dose Selection for Brain Metastases. Clinical and translational science · 16 Oct 2026 PMID 42886004
- Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study. Signal transduction and targeted therapy · 12 Aug 2026 PMID 42586967
- Activation of the NF-κB/ALDH1A1 signaling promotes non-mutational resistance to EGFR-TKIs in non-small cell lung cancer. Oncogene · 23 Jul 2026 PMID 42493544
- Beyond Amplification: Precision Approaches to Targeting HER2. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Jul 2026 PMID 42423636
- A tri-modal biosensor based on alkyne-functionalized gold nanoparticles and molecular beacon for detection of resistance-related point mutations in epidermal growth factor receptor-tyrosine kinase inhibitors. Molecular biology reports · 22 May 2026 PMID 42171913
By study type
Clinical trials (3)
- Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study. Signal transduction and targeted therapy · 12 Aug 2026 PMID 42586967
- Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377073
- Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. Hypertension (Dallas, Tex. : 1979) · 20 May 2026 PMID 42158981
Observational studies and case reports (5)
- Retrospective observational study of transcatheter arterial chemoembolization (TACE) combined with PD-1 inhibitor and tyrosine kinase inhibitor (TKI) in advanced hepatocellular carcinoma. Medicine · 17 Oct 2026 PMID 42888556
- Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation. PloS one · 29 Sept 2026 PMID 42809552
- Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study. Leukemia research · 4 Aug 2026 PMID 42551129
- The Combined Therapeutic Effect of Lenvatinib and ADI-PEG 20 in Advanced Hepatocellular Carcinoma: A Case Report. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379775
- Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study. Leukemia · 18 Jun 2026 PMID 42315627
Human data, design not indexed (6)
- Development, validation, and pilot-testing of a comprehensive patient-reported EORTC custom questionnaire for monitoring real-world tyrosine kinase toxicity in chronic myeloid leukemia. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 12 Nov 2026 PMID 43018785
- A Systematic Intracranial Exposure-Response Evaluation of Brain-Penetrant Inhibitors: Informing Dose Selection for Brain Metastases. Clinical and translational science · 16 Oct 2026 PMID 42886004
- Modifiable determinants of adherence to tyrosine kinase inhibitors in classical myeloproliferative neoplasms: A mixed-methods systematic review protocol. PloS one · 18 Sept 2026 PMID 42758748
- Beyond Amplification: Precision Approaches to Targeting HER2. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Jul 2026 PMID 42423636
- Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. Blood advances · 25 Jun 2026 PMID 42349018
- A tri-modal biosensor based on alkyne-functionalized gold nanoparticles and molecular beacon for detection of resistance-related point mutations in epidermal growth factor receptor-tyrosine kinase inhibitors. Molecular biology reports · 22 May 2026 PMID 42171913
Preclinical: animal, cell and lab studies (3)
- Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor? Journal of hematology & oncology · 27 Oct 2026 PMID 42934771
- Activation of the NF-κB/ALDH1A1 signaling promotes non-mutational resistance to EGFR-TKIs in non-small cell lung cancer. Oncogene · 23 Jul 2026 PMID 42493544
- FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma. ACS applied materials & interfaces · 22 Jun 2026 PMID 42328782
Written from 17 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-20 by GPT. Drafted by language models from published abstracts; not medical advice.